-
Q4 sprint: important products of famous enterprises such as Hengrui, Fosun, hausen, Huahai, dongyangguang and Xinda will be available
Time of Update: 2018-09-29
September is coming to an end Which blockbuster drugs are expected to be launched in the fourth quarter of 2018? Let's look at the following: competition for the first listing of new drugs Hengrui, Xi
-
Hengrui, Zhengda Tianqing anti-tumor drug price negotiation succeeded! Will the sales of androtinib exceed 1 billion this year?
Time of Update: 2018-09-28
As the only two local enterprises shortlisted, aiyang and fukewei are successfully included in the medical insurance For Hengrui and Zhengda Tianqing, it undoubtedly provides a strong guarantee for th
-
In 2018, 49 drugs were modified in the instruction manual, 23 injections were eye-catching, and a large number of children were forbidden to use drugs
Time of Update: 2018-09-21
The basic function of drug instructions is to guide the safe and rational use of drugs In recent years, in order to strengthen drug supervision, further protect the public drug safety and standardize
-
"R & D first brother" change? Half a year's R & D investment is nearly 1.2 billion, and this pharmaceutical company may win the first car-t in China
Time of Update: 2018-09-13
Wonderful content recently, Fosun Pharmaceutical announced that its investment company Fosun Kate's car-t product fkc876 was officially approved by the clinical trial of the State Food and drug admini
-
In 2018, three domestic tinies will be listed one after another. Who will become the fourth approved domestic tinies in the year?
Time of Update: 2018-09-11
A few days ago, fujiquitinib, a class 1 new drug developed by Hutchison Whampoa in 13 years, was officially approved for the market This is the third domestic Tinian drug approved this year The first
-
Hengrui, Shiyao, Yunnan Baiyao, yaomingkant and other companies with a market value of 100 billion have made great achievements in half a year. Who makes the most money?
Time of Update: 2018-08-23
When the mid-year performance of pharmaceutical enterprises appeared again, as of August 22, 141 pharmaceutical companies had released the mid-2018 performance What are the performances of the pharmac
-
Hengrui pyrrolidine is approved for listing! Consistency evaluation of three class 1 new drugs and six over 1 billion injections
Time of Update: 2018-08-15
The highlights came a few days ago when Hengrui pharmaceutical released its 2018 semi annual report The company's operating revenue was 7.761 billion yuan, an increase of 22.32% year-on-year; the net
-
Shangyao, Hengrui and China Resources SECCO passed the consistency evaluation! When the policy combination comes, the first batch of products to be eliminated are
Time of Update: 2018-08-15
If the products fail to pass the consistency evaluation, slow-moving products, or are eliminated by the policy line, or by the market, the time limit is coming And the first thing that generic drugs r
-
Anti ed domestic class 1 new drug is coming! 3 billion market to be challenged, can Viacom hold on?
Time of Update: 2018-08-10
Wonderful content recently, China Pharmaceutical announced that the phase II and phase III clinical application of tpn729ma, a new anti ed class 1 drug of Tianfang Pharmaceutical Co., Ltd., a wholly-o
-
Take a closer look at the changes in the original research market of six heavy-duty varieties: which products are fierce in "grabbing"? How did Hengrui, Qilu and Zhengda Tianqing perform?
Time of Update: 2018-08-07
In many developed countries, the price and market share of generic drugs will decrease significantly after the expiration of the original patent However, in China, many imported drugs still maintain h
-
Cullen, zoom in! In the first half of the year, net profit tripled, and two class 1 new drugs challenged the global market of $1 billion
Time of Update: 2018-08-07
Highlights recently, Kelun pharmaceutical released the semi annual performance express in 2018 The company realized a net profit of 774 million yuan attributable to shareholders of listed companies, a
-
Xinlitai's new drug "tegrilol" came out, and the antithrombotic 30 billion market ushered in a new round of reshuffle
Time of Update: 2018-08-06
Recently, Shenzhen xinlitai Pharmaceutical Co., Ltd received the approval document for drug registration of tegrilol tablets approved and issued by the State Drug Administration The board of directors
-
New drug gap: list of new drugs that have been listed in the United States but not in China
Time of Update: 2018-08-02
CDE recently organized a symposium on accelerating the review and approval of imported drugs, in which it mentioned that "we should speed up the review and approval of some imported drugs in an orderl
-
"289 limit" is coming! 13 varieties pass customs, 36 are on the road, and nearly 200 "three no varieties" are out?
Time of Update: 2018-08-01
On July 31, CDE issued a notice that in order to accelerate the consistency evaluation of "289 varieties", it specially combed and investigated the domestic unique varieties in the 289 catalog, formed
-
The consistency evaluation of double weight varieties has passed 3 enterprises! Zhengda Tianqing, Haizheng, Xiansheng and other first-hand opportunities, which varieties will be more than 3?
Time of Update: 2018-07-27
On July 26, the State Drug Administration issued the announcement that the fifth batch of montmorillonite and other 16 varieties and specifications passed the conformity evaluation of quality and effi
-
The enthusiasm of applying for imported generic drugs is gradually rising: overseas data sharing is good! Which can pass customs faster?
Time of Update: 2018-07-26
The spring of overseas generic drugs has come On July 10, 2018, the State Drug Administration issued the notice of "technical guidelines for accepting data of overseas clinical trials of drugs" (No 52
-
Special varieties of "Major new drug creation" approved for marketing in the first half of 2018
Time of Update: 2018-07-25
In 2006, the State Council released the outline of national medium and long term science and technology development plan (2006-2020), which made an overall plan for China's science and technology deve
-
Sales growth of up to 3683%! After the negotiation of 16 anticancer drugs, "price for quantity" has given birth to 3 billion varieties
Time of Update: 2018-07-25
A new round of national health insurance negotiation is in full swing, and Wuhan has taken the initiative Recently, Hubei Province issued the notice of Wuhan medical materials procurement management o
-
Hubei health and Health Commission supports the substitution of generic drugs! Dozens of multinational pharmaceutical enterprises were affected, and a batch of over 2 billion yuan varieties ushered in the big test!
Time of Update: 2018-07-25
In the follow-up policy of consistency evaluation, another province has made a new breakthrough Hubei not only opened up a green channel for high-quality generic drugs, so that high-quality drugs can
-
289 catalog failed to do? Delay or elimination? Disposal plan is coming
Time of Update: 2018-07-23
At present, it is less than 5 months before 289 generic drugs quality and efficacy consistency evaluation is completed According to the latest data provided by the State Drug Administration, 15 batche
